1. Caporro, M., Disanto, G., Gobbi, C. & Zecca, C. Two decades of subcutaneous glatiramer acetate injection: Current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment. Patient Prefer. Adherence 8, 1123–1134 (2014).
2. Camargo-Mascarenhas, R. P. et al. Development and characterization of liposomes containing glatiramer acetate for multiple sclerosis. Int. J. Appl. Biol. 7(2), 303–313 (2016).
3. Marom, E., & Rubnov, S. Mapi Pharma Ltd, Depot systems comprising glatiramer or pharmacologically acceptable salt thereof. U.S. Patent 8,377,885 (2013).
4. Geister, U., Schweizer, S., Buerger, M., Stefan, R., Huber, G.et al. Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate. U.S. Patent Application 14/653,022 (2016).
5. Melendez-Torres, G. J. et al. Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: Systematic review and network meta-analysis of trials including recommended dosages. BMC Neurol. 18(1), 162 (2018).